Bank of Montreal
BCLI

Bank of Montreal’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Bank of Montreal’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,193
Closed -$433K – 4764
2020
Q2 		$433K Sell
2,193
-367
-14% -$39.6K ﹤0.01% 2334
2020
Q1 		$180K Buy
+2,560
New +$200K ﹤0.01% 2373

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of Montreal's BCLI Position: Q2 2021 in Review

Bank of Montreal sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2021, closing a stake of 62 shares — an estimated $3K sold.

Bank of Montreal first reported a position in BCLI in Q3 2014 and held it in 21 quarters. The position peaked at $474K in Q2 2020. 57 funds tracked by Wall St. Rank hold BCLI as of Q2 2021.

  • Bank of Montreal reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2021 after selling out during the quarter.
  • Bank of Montreal sold 62 BRAINSTORM CELL THERAPUTC shares in Q2 2021, an estimated $3K.
  • Bank of Montreal first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2014 and held it in 21 quarters.
  • Bank of Montreal's BRAINSTORM CELL THERAPUTC position peaked at $474K in Q2 2020.
  • 57 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.